136 related articles for article (PubMed ID: 10905752)
1. Drug safety in relation to efficacy: the view of a clinical pharmacologist.
Sjöqvist F
Pharmacol Toxicol; 2000; 86 Suppl 1():30-2. PubMed ID: 10905752
[TBL] [Abstract][Full Text] [Related]
2. Monitoring medicines use: the role of the clinical pharmacologist.
Williams D
Br J Clin Pharmacol; 2012 Oct; 74(4):685-90. PubMed ID: 22554404
[TBL] [Abstract][Full Text] [Related]
3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system.
Sessa M; Bernardi FF; Vitale A; Schiavone B; Gritti G; Mascolo A; Bertini M; Scavone C; Sportiello L; Rossi F; Capuano A
J Clin Pharm Ther; 2018 Dec; 43(6):867-876. PubMed ID: 30014479
[TBL] [Abstract][Full Text] [Related]
5. [Adverse drug reactions and prescription errors: morbi-mortality].
Chaio S; Toibaro J; Valicenti P; Saidón P
Medicina (B Aires); 2013; 73(2):111-8. PubMed ID: 23570758
[TBL] [Abstract][Full Text] [Related]
6. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
Kurz X; Perez-Gutthann S;
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):245-252. PubMed ID: 29327451
[No Abstract] [Full Text] [Related]
7. Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention.
Goedecke T; Ord K; Newbould V; Brosch S; Arlett P
Drug Saf; 2016 Jun; 39(6):491-500. PubMed ID: 26940903
[TBL] [Abstract][Full Text] [Related]
8. [Recording and assessment of medication errors : Experience of the Drug Commission of the German Medical Association].
Köberle U; Stammschulte T; Gundert-Remy U; Pitzer M; Bräutigam K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1066-1074. PubMed ID: 30022236
[TBL] [Abstract][Full Text] [Related]
9. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
[TBL] [Abstract][Full Text] [Related]
10. [Understanding and reducing the risk of adverse drug reactions in pediatric patients].
Gotta V; van den Anker J; Pfister M
Ther Umsch; 2015 Dec; 72(11-12):679-86. PubMed ID: 26654811
[TBL] [Abstract][Full Text] [Related]
11. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs.
Lapeyre-Mestre M; Montastruc F
Therapie; 2019 Apr; 74(2):209-214. PubMed ID: 30792079
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
Schäublin M
Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
[TBL] [Abstract][Full Text] [Related]
13. The role of the clinical pharmacologist in the management of adverse drug reactions.
Moore N
Drug Saf; 2001 Jan; 24(1):1-7. PubMed ID: 11219484
[TBL] [Abstract][Full Text] [Related]
14. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug events and medication errors in Australia.
Runciman WB; Roughead EE; Semple SJ; Adams RJ
Int J Qual Health Care; 2003 Dec; 15 Suppl 1():i49-59. PubMed ID: 14660523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacovigilance for children's sake.
Star K; Edwards IR
Drug Saf; 2014 Feb; 37(2):91-8. PubMed ID: 24446277
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance in pediatrics.
Bouquet É; Star K; Jonville-Béra AP; Durrieu G
Therapie; 2018 Apr; 73(2):171-180. PubMed ID: 29598957
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics.
Kaguelidou F; Durrieu G; Clavenna A
Therapie; 2019 Apr; 74(2):315-324. PubMed ID: 30773345
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions: an integrated approach.
Ti TY; MacLeod SM
Bratisl Lek Listy; 1991 Nov; 92(11):531-3. PubMed ID: 1806162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
